Pharmaceutical Executive Digest Europe - March 4, 2009 - (Page 5) Training and Development Enter the mini-MBA. These are courses based on full MBA programmes, but squeezing the core curriculum into a frenetic four or five-day period. “We have a strategy day, a marketing day, a finance day and so on. It’s very intense,” says Rosie Bernard, head of Pharmaceutical Training International (PTI). With attendees being given a year’s worth of information in a week, the course folder at the PTI event was described by one attendee as being “heavy as an office chair.” Skills learned in MBA training will continue to be relevant as pharma re-orients itself… PTI runs about 60 technical courses for the pharmaceutical industry. According to Bernard, the mini-MBA is the most generic. “It is more creative, more strategic and aimed at a higher level of delegate,” she says. Typical class sizes are around 10–20. “We wouldn’t do it with less than eight people, and of course they all need to be at a certain level. It’s very much reliant on discussion between participants, so they’re learning from each other.” Whilst Taylor at Crawford Scientific supports all forms of management training, he does wonders if there really can be such a thing as a pharma MBA. “I think MBA’s can be skewed for certain industries and some are of great value, but a true pharma MBA would be a ‘woolly’ affair by dint of the fact that it’s such a massive topic. It would have to generic a great deal to appeal to a broad audience.” Taylor may have a point, but proponents of MBA training in general would say the skills learned will continue to be relevant as pharma re-orients itself. Francis van den Bosch, managing director of Brussels-based Management Centre Europe, which also runs a pharma mini-MBA points out that the recession ‘hides’ fundamental changes that are going on in the pharma industry, changes that will still be there after the recession has gone. “If anything, the recession accelerates these changes. Managers, including middle managers in pharma, have to come to grips with these changes, which one has to prepare for now.” MISS IT, MISS OUT! Ensure you receive Pharm Exec Europe every week. Click here to subscribe for FREE now! pharmexec.com 2 FROM THE EDITOR / NEWS 3 11 PHARMA MBAs NEWS 6 BIO-ENTREPRENEUR SCHOOL 8 SALES FORCE EFFECTIVENESS 10 GSK’S PRICE CUTS 13 CALENDAR 14 ON THE MOVE http://www.pharmexeceurope.com/europharmexec/newsletter/subscribeNewsletter.jsp http://www.iir-events.com/IIR-conf/PTI/EventView.aspx?EventID=1013 http://www.iir-events.com/IIR-conf/PTI/EventView.aspx?EventID=1013 http://www.mce-ama.com/ http://www.mce-ama.com/
Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Digest Europe - March 4, 2009 Pharmaceutical Executive Digest Europe - March 4, 2009 Contents From the Editor Training and Development Sales Opinion Calendar On the Move Pharmaceutical Executive Digest Europe - March 4, 2009 Pharmaceutical Executive Digest Europe - March 4, 2009 - Contents (Page 1) Pharmaceutical Executive Digest Europe - March 4, 2009 - From the Editor (Page 2) Pharmaceutical Executive Digest Europe - March 4, 2009 - Training and Development (Page 3) Pharmaceutical Executive Digest Europe - March 4, 2009 - Training and Development (Page 4) Pharmaceutical Executive Digest Europe - March 4, 2009 - Training and Development (Page 5) Pharmaceutical Executive Digest Europe - March 4, 2009 - Training and Development (Page 6) Pharmaceutical Executive Digest Europe - March 4, 2009 - Training and Development (Page 7) Pharmaceutical Executive Digest Europe - March 4, 2009 - Sales (Page 8) Pharmaceutical Executive Digest Europe - March 4, 2009 - Sales (Page 9) Pharmaceutical Executive Digest Europe - March 4, 2009 - Opinion (Page 10) Pharmaceutical Executive Digest Europe - March 4, 2009 - Opinion (Page 11) Pharmaceutical Executive Digest Europe - March 4, 2009 - Opinion (Page 12) Pharmaceutical Executive Digest Europe - March 4, 2009 - Calendar (Page 13) Pharmaceutical Executive Digest Europe - March 4, 2009 - On the Move (Page 14)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.